Wall Street analyst estimates for REGENXBIO Inc. (RGNX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
Analyst Consensus
| Strong Buy | 1 |
| Buy | 13 |
| Hold | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (1-5) | 0.70 |
Valuation Ratios
| Price / Book | 5.87 |
| EV / EBITDA | -3.56 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $10.4M | $218.5M | $35.2M | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M |
| Cost of Revenue | $959000 | $1.7M | $9.6M | $8.2M | $35.7M | $51.8M | $54.5M | $37.2M | $33.6M | $20.3M |
| Gross Profit | $3.6M | $8.7M | $208.9M | $27.0M | $118.9M | $418.5M | $58.2M | $53.0M | $49.8M | $150.1M |
| Research & Development | $45.5M | $57.2M | $83.9M | $124.2M | $166.3M | $181.4M | $242.5M | $232.3M | $208.5M | $228.3M |
| Selling, General & Admin | $23.6M | $27.2M | $36.9M | $51.8M | $63.8M | $79.3M | $85.3M | $88.5M | $76.6M | $82.9M |
| Operating Expenses | $69.0M | $84.6M | $120.8M | $176.0M | $238.1M | $258.5M | $321.1M | $321.2M | $283.1M | $311.3M |
| Operating Income | -$65.3M | -$75.9M | $88.1M | -$149.0M | -$119.2M | $160.0M | -$262.9M | -$268.1M | -$233.3M | -$161.2M |
| EBITDA | -$64.8M | -$73.2M | $92.1M | -$90.3M | -$96.8M | $177.1M | -$244.2M | -$239.5M | -$198.2M | -$133.3M |
| Interest Expense | 0 | 0 | 0 | 0 | $771000 | $26.3M | $23.3M | $6.9M | $12.7M | $45.0M |
| Pre-tax Income | -$63.4M | -$73.2M | $104.1M | -$97.5M | -$106.0M | $141.2M | -$280.4M | -$263.6M | -$227.1M | -$193.9M |
| Income Tax | -$435000 | $686000 | $4.2M | -$2.8M | $5.2M | $13.4M | -$84000 | -$152000 | 0 | 0 |
| Net Income | -$63.0M | -$73.2M | $99.9M | -$94.7M | -$111.2M | $127.8M | -$280.3M | -$263.5M | -$227.1M | -$193.9M |
| EPS | $-2.38 | $-2.45 | $2.73 | $-2.58 | $-2.98 | $3.01 | $-6.50 | $-6.02 | $-4.59 | $-3.76 |
| EPS (Diluted) | $-2.38 | $-2.45 | $2.73 | $-2.58 | $-2.98 | $2.91 | $-6.50 | $-6.02 | $-4.59 | $-3.76 |
| Shares Outstanding (Diluted) | $26.4M | $29.9M | $36.6M | $36.7M | $37.3M | $43.9M | $43.2M | $43.7M | $49.5M | $51.6M |
Price
| Price | $7.98 |
| Market Cap | $413M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABSI · CRVS · FDMT · GOSS · KALV · MLTX · OLMA
Explore sector: Healthcare · Biotechnology
More sections of RGNX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks